Short Interest in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Decreases By 13.7%

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) saw a large drop in short interest in the month of March. As of March 13th, there was short interest totaling 278,317 shares, a drop of 13.7% from the February 26th total of 322,619 shares. Based on an average trading volume of 27,811 shares, the days-to-cover ratio is currently 10.0 days. Approximately 0.2% of the shares of the company are sold short.

HUTCHMED Stock Performance

NASDAQ:HCM traded up $0.34 during trading hours on Tuesday, reaching $14.64. The company had a trading volume of 10,371 shares, compared to its average volume of 37,004. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.83 and a current ratio of 4.96. The stock has a 50-day moving average of $14.60 and a two-hundred day moving average of $14.79. HUTCHMED has a one year low of $11.51 and a one year high of $19.50.

HUTCHMED (NASDAQ:HCM) last issued its earnings results on Friday, March 6th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $2.50 by ($2.49). The firm had revenue of $135.42 million for the quarter, compared to the consensus estimate of $290.50 million. As a group, research analysts predict that HUTCHMED will post 0.16 EPS for the current fiscal year.

Institutional Trading of HUTCHMED

Several large investors have recently added to or reduced their stakes in the company. State Street Corp raised its stake in shares of HUTCHMED by 1.2% in the fourth quarter. State Street Corp now owns 321,305 shares of the company’s stock valued at $4,283,000 after acquiring an additional 3,801 shares during the last quarter. M&G PLC increased its holdings in HUTCHMED by 26.7% during the 4th quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after purchasing an additional 54,601 shares in the last quarter. Amundi raised its position in HUTCHMED by 41.9% in the 3rd quarter. Amundi now owns 223,330 shares of the company’s stock valued at $3,620,000 after purchasing an additional 65,898 shares during the last quarter. Jane Street Group LLC boosted its stake in HUTCHMED by 128.0% in the first quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after purchasing an additional 124,771 shares in the last quarter. Finally, UBS Group AG boosted its stake in HUTCHMED by 112.8% in the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after purchasing an additional 72,614 shares in the last quarter. 8.82% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

HCM has been the subject of a number of recent research reports. Jefferies Financial Group upgraded HUTCHMED to a “strong-buy” rating in a research note on Monday, January 19th. Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a report on Thursday, January 22nd. Bank of America dropped their price objective on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, March 10th. Finally, Wall Street Zen cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $16.88.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.